- Clinical Trials Arena
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

Biogen’s BIIB059 yields positive results in Phase II SLE study

The SLE part of the trial evaluated 450mg dose of a BIIB059 injected subcutaneously once every four weeks. Credit: Myriams-Fotos from Pixabay.